Material Intellectual Property. Schedule 7.05(c) contains an accurate list of the Obligor Intellectual Property that is material to the Borrower’s business with an indication as to whether the applicable Obligor owns or has an exclusive or non-exclusive license to such Obligor Intellectual Property.
Material Intellectual Property. Schedule 7.05(c) contains a complete and accurate list of the Obligor Intellectual Property the loss of which, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect upon the Borrower’s business with an indication as to whether the applicable Obligor owns or has an exclusive or non-exclusive license to such Obligor Intellectual Property.
Material Intellectual Property. Schedule 7.05(c) of the Disclosure Letter (as amended from time to time by Borrower in accordance with Section 7.21) contains an accurate list of the Obligor Intellectual Property that is material to any Obligor’s business with an indication as to whether the applicable Obligor owns or has an exclusive or non-exclusive license to such Obligor Intellectual Property.
Material Intellectual Property. No Obligor shall, nor shall any Obligor permit any Subsidiary (other than an Excluded Subsidiary) to, enter into any arrangement, directly or indirectly, with any Excluded Subsidiary whereby such Obligor or such Subsidiary shall sell, transfer, lease or otherwise dispose of (whether in one transaction or in a series of transactions), to an Excluded Subsidiary any Intellectual Property, whether now owned or hereafter acquired, that is material to the business of the Borrower and its Subsidiaries (other than Excluded Subseries), taken as a whole.
Material Intellectual Property. Permit any Subsidiary that is not a Guarantor to own any material Intellectual Property or any Intellectual Property material to the operation of the Borrower’s or any Guarantor’s business.
Material Intellectual Property. Notwithstanding anything to the contrary in this Agreement, (x) no Credit Party or any of its Restricted Subsidiaries shall (whether by Investment, Restricted Payment, Disposition or otherwise) transfer any ownership right, or exclusive license or exclusive right to, any Material Intellectual Property to any Unrestricted Subsidiary (including by transferring any Capital Stock of a member of the Restricted Group to an Unrestricted Subsidiary) and (y) to the extent that any Restricted Subsidiary owns, or holds exclusive licenses or rights to, any Material Intellectual Property, no such Restricted Subsidiary may be designated as an Unrestricted Subsidiary.
Material Intellectual Property. [None.] [***] Confidential treatment has been requested for the bracketed portions. The confidential redacted portion has been omitted and filed separately with the Securities and Exchange Commission. This ACCESSSION AGREEMENT NO. [__], dated as of [________], [____], relating to the Guaranty and Security Agreement (the “Security Agreement”), dated as of [________], [____], among the Wholly Owned Opco Guarantors identified therein and Deutsche Bank Trust Company Americas, as Collateral Agent.
Material Intellectual Property. No Material Intellectual Property may be owned or held (including by way of an exclusive license of such Material Intellectual Property) by any Person that is not a Credit Party.
Material Intellectual Property. Peregrine has exclusive rights to market and sell world-wide the bavituximab family of antibodies for treatment of all solid tumors, non-small cell lung cancer, breast cancer, Hepatitis C and HIV through the following list of patents and license agreements: Naked anti-PS antibodies Univ. of Texas System 000 X. 0xx Xxxxxx, Xxxxxx, XX 00000 Upon exp of Patents 2018 Yes Transferable to successor VTA Univ. of Texas System 000 X. 0xx Xxxxxx, Xxxxxx, XX 00000 Upon exp of Patents 2014 Yes Transferable to successor bavituximab Avanir Pharmaceuticals 000 Xxxxxxxxxx, Xxxxx 000, Xxxxx Xxxxx, XX 00000 10 year from first commercial sale per country N/A Yes Transferable to successor Anti-PS antibodies Univ. of Texas System 000 X. 0xx Xxxxxx, Xxxxxx, XX 00000 Upon exp of Patents 2022 Yes Transferable to successor Peregrine has exclusive rights to market and sell world-wide (except China) the product known as Cotara® (a chimeric antibody labeled with radioactive iodine-131 that targets necrotic tumor cells) for treatment of brain, colon, liver, lung, prostate and pancreatic cancers, through the following list of patents and license agreements: CONTINUOUS LARGE SCALE METHOD FOR PROTEIN LABELING (US) 10/877,959 06/25/04 CONTINUOUS LARGE SCALE METHOD FOR PROTEIN LABELING (PCT) PCT/US04/020492 11/25/05 CONTINUOUS LARGE SCALE METHOD FOR PROTEIN LABELING (PCT) 2004253924 11/24/05 CONTINUOUS LARGE SCALE METHOD FOR PROTEIN LABELING (PCT) 200480017742.X 12/23/05 CONTINUOUS LARGE SCALE METHOD FOR PROTEIN LABELING (EPO – Belgium, Switzerland, Germany, Denmark, Finland, France, Great Britain, Ireland, Netherlands & Sweden) 04785799.0 01/05/06 CONTINUOUS LARGE SCALE METHOD FOR PROTEIN LABELING (HK) 06109573.0 08/28/06 CONTINUOUS LARGE SCALE METHOD FOR PROTEIN LABELING (EPO DIV) 08010871.5 06/13/08 CONTINUOUS LARGE SCALE METHOD FOR PROTEIN LABELING (India) 419/DELNP/2006 01/23/06 CONTINUOUS LARGE SCALE METHOD FOR PROTEIN LABELING (New Zealand) 543495 11/10/05 Specific binding proteins including antibodies which bind to the necrotic centre of tumours, and uses thereof (Australia) 766564 7/2/1999 Specific binding proteins including antibodies which bind to the necrotic centre of tumours, and uses thereof (Canada) 2336114 7/2/1999 Specific binding proteins including antibodies which bind to the necrotic centre of tumours, and uses thereof (EPO – Denmark, France, Great Britain, Netherlands) EP1092028B1 7/2/1999 Specific binding proteins including antibodies which bind to the necrotic centr...
Material Intellectual Property. Assign, transfer, or exclusively license or exclusively sublicense any Material Intellectual Property to any Subsidiary that is not a Subsidiary Guarantor other than such assignments, transfers, licenses or sublicenses of Material Intellectual Property owned or licensed by, or otherwise used in the business of, the Hawthorne Entities contemplated to be assigned, transferred or exclusively licensed to the Hawthorne Entities by the Project Xxx Transaction.
